Toronto-based artificial intelligence (AI) firm Predictmedix (CSE: PMED; OTCQB: PMEDF) has launched screening technologies that will assist businesses by detecting potential COVID-19 infection and other illnesses. The versatile technology will also be used to scan physical spaces to ensure that people are following protocol such as physical distancing and the mandated wearing of face masks.
Earlier this month, Predictmedix filed for a US patent for COVID-19 testing and the technology is being offered to businesses as the world shifts into a new normal. The ground-breaking technology has a wide range of uses and the publicly traded company is expected to see a rapid increase in its share price in the coming weeks amid increased awareness and retailer adoption.
One of the most encouraging new developments for Predictmedix is mass screening for COVID-19. Retailers, restaurants, landlords, and any business with a physical presence will be able to utilize the AI technology to screen for symptoms of the coronavirus as well as for other illnesses. Predictmedix has agreements in place with multi-billion-dollar global conglomerates and the company has further bolstered its team by appointing Kapil Raval, director of AI Business Development at Microsoft, as chairman of their board to expedite Predictmedix’s business development initiatives as the company expands into several markets. Predictmedix was co-founded by Toronto-based Dr. Rahul Kushwah and entrepreneur Sheldon Kales and the company has a team which not only excels in AI related expertise but also in medicine.
